Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc.ABOS · Entity 6281 | CFO & Chief Business Officer | January 21, 2026 | January 23, 2026 |
| ELUTIA INC.ELUT · Entity 7342 | Director · 10% owner | May 29, 2025 | June 02, 2025 |
| Quantum-Si IncCAPA · Entity 6440 | Director · 10% owner | September 03, 2020 | September 03, 2020 |
| TELA Bio, Inc.TELA · Entity 7381 | Director | November 08, 2019 | November 14, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acumen Pharmaceuticals, Inc.
Report date January 21, 2026 · Filed January 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 304,924 |
Ending reported balance
After 2026-01-22 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-01-21 · Sale · Disposed 2,473 · Balance 306,611 F1: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024. F2: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7650 to $1.8700. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 2 · 2026-01-22 · Sale · Disposed 1,687 · Balance 304,924 F1: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024.
F2: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7650 to $1.8700. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
ELUTIA INC.
Report date May 29, 2025 · Filed June 02, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.65 · Expires 2035-05-29 | Direct | 60,339 |
Reported balance
After 2025-05-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-29 · Grant · Acquired 60,339 · Balance 60,339 F1: This option was granted automatically under the Issuer's Non-Employee Director Compensation Program and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continuing in service on the Issuer's board of directors through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted automatically under the Issuer's Non-Employee Director Compensation Program and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continuing in service on the Issuer's board of directors through the applicable vesting date.
Quantum-Si Inc
Report date September 03, 2020 · Filed September 03, 2020
Jointly reported with HighCape Capital Acquisition LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-09-03 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The shares of Class B common stock are convertible for shares of the Issuer's Class A common stock as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-240283) (the "Registration Statement") and have no expiration date. The shares of Class B common stock beneficially owned by the Reporting Persons include up to 375,000 shares of Class B common stock subject to forfeiture to the Issuer depending on the extent to which the underwriters' over-allotment option is exercised in connection with the Issuer's initial public offering of units, as described in the Registration Statement. F2: HighCape Capital Acquisition LLC is the record holder of the securities reported herein. Matt Zuga is the sole manager of HighCape Capital Acquisition LLC and has voting and investment discretion with respect to the securities held of record by HighCape Capital Acquisition LLC. Mr. Zuga disclaims any beneficial ownership of the securities held by HighCape Capital Acquisition LLC other than to the extent of any pecuniary interest they may have therein, directly or indirectly. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Class B common stock are convertible for shares of the Issuer's Class A common stock as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-240283) (the "Registration Statement") and have no expiration date. The shares of Class B common stock beneficially owned by the Reporting Persons include up to 375,000 shares of Class B common stock subject to forfeiture to the Issuer depending on the extent to which the underwriters' over-allotment option is exercised in connection with the Issuer's initial public offering of units, as described in the Registration Statement.
F2: HighCape Capital Acquisition LLC is the record holder of the securities reported herein. Matt Zuga is the sole manager of HighCape Capital Acquisition LLC and has voting and investment discretion with respect to the securities held of record by HighCape Capital Acquisition LLC. Mr. Zuga disclaims any beneficial ownership of the securities held by HighCape Capital Acquisition LLC other than to the extent of any pecuniary interest they may have therein, directly or indirectly.
TELA Bio, Inc.
Report date November 08, 2019 · Filed November 14, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy HighCape Partners, L.P. | 12,675 |
Reported balance
After 2019-11-08 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-11-08 · Purchase · Acquired 10,220 · Balance 12,675 F1: Reflects 2,455 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a). |
| Common StockSEC Table I · non-derivative | IndirectBy HighCape Partners, L.P. | 12,944 |
Reported balance
After 2019-11-13 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2019-11-13 · Conversion · Acquired 269 · Balance 12,944 F3: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. |
| Common StockSEC Table I · non-derivative | IndirectBy HighCape Partners, L.P. | 15,875 |
Reported balance
After 2019-11-13 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2019-11-13 · Conversion · Acquired 2,931 · Balance 15,875 F4: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. |
| Common StockSEC Table I · non-derivative | IndirectBy HighCape Partners QP, L.P. | 260,808 |
Reported balance
After 2019-11-08 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2019-11-08 · Purchase · Acquired 75,901 · Balance 260,808 F2: Reflects 183,907 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a). |
| Common StockSEC Table I · non-derivative | IndirectBy HighCape Partners QP, L.P. | 280,790 |
Reported balance
After 2019-11-13 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2019-11-13 · Conversion · Acquired 19,982 · Balance 280,790 F3: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. |
| Common StockSEC Table I · non-derivative | IndirectBy HighCape Partners QP, L.P. | 498,606 |
Reported balance
After 2019-11-13 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2019-11-13 · Conversion · Acquired 217,816 · Balance 498,606 F4: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy HighCape Partners QP, L.P. | 0 |
Reported balance
After 2019-11-13 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-11-13 · Conversion · Disposed 493,357 · Balance 0 F3: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F5: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy HighCape Partners, L.P. | 0 |
Reported balance
After 2019-11-13 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-11-13 · Conversion · Disposed 6,643 · Balance 0 F3: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F5: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy HighCape Partners QP, L.P. | 0 |
Reported balance
After 2019-11-13 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-11-13 · Conversion · Disposed 5,377,928 · Balance 0 F4: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F5: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy HighCape Partners, L.P. | 0 |
Reported balance
After 2019-11-13 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-11-13 · Conversion · Disposed 72,417 · Balance 0 F4: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F5: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.16 · Expires 2027-01-18 | IndirectBy HighCape Partners QP, L.P. | 0 |
Reported balance
After 2019-11-13 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-11-13 · Conversion · Disposed 123,653 · Balance 0 F6: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.65 · Expires 2027-01-18 | IndirectBy HighCape Partners QP, L.P. | 123,653 |
Reported balance
After 2019-11-13 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2019-11-13 · Conversion · Acquired 123,653 · Balance 123,653 F6: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.16 · Expires 2027-01-18 | IndirectBy HighCape Partners, L.P. | 0 |
Reported balance
After 2019-11-13 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2019-11-13 · Conversion · Disposed 1,665 · Balance 0 F6: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.65 · Expires 2027-01-18 | IndirectBy HighCape Partners, L.P. | 1,665 |
Reported balance
After 2019-11-13 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2019-11-13 · Conversion · Acquired 1,665 · Balance 1,665 F6: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects 2,455 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a).
F2: Reflects 183,907 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a).
F3: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.
F4: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.
F5: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019.
F6: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 22, 2026 Filed Jan 23, 2026 23:11 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 1,687 | $1.86 | $3,137.82 |
DisclosureSEC source: 0001628280-26-003347 · wk-form4_1769209883.xml · nonDerivative · entry 2 Zuga Matt · CIK 0001790214 · CFO & Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 304,924 F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 23:11 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 2,473 | $1.81 | $4,469.21 |
DisclosureSEC source: 0001628280-26-003347 · wk-form4_1769209883.xml · nonDerivative · entry 1 Zuga Matt · CIK 0001790214 · CFO & Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 306,611 F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7650 to $1.8700. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 23:32 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantEmployee Stock Option (right to buy) · Derivative | 148,700 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001628280-26-002961 · wk-form4_1769038322.xml · derivative · entry 2 Zuga Matt · CIK 0001790214 · CFO & Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,700 Underlying: Common Stock · 148,700 shares Expires 2036-01-16 F2 · derivative.exercise_date: The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 23:32 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantCommon Stock | 99,133 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-002961 · wk-form4_1769038322.xml · nonDerivative · entry 1 Zuga Matt · CIK 0001790214 · CFO & Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 309,084 F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 23:52 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 6,888 | $1.82 | $12,512.74 |
DisclosureSEC source: 0001628280-26-001898 · wk-form4_1768261959.xml · nonDerivative · entry 1 Zuga Matt · CIK 0001790214 · CFO & Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,951 F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7200 to $1.9500. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 02:31 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 1,700 | $1.99 | $3,376.54 |
DisclosureSEC source: 0001628280-26-001265 · wk-form4_1767839507.xml · nonDerivative · entry 4 Zuga Matt · CIK 0001790214 · CFO & Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,839 F5 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025. F6 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9600 to $2.0100. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 02:31 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 4,105 | $2.00 | $8,189.48 |
DisclosureSEC source: 0001628280-26-001265 · wk-form4_1767839507.xml · nonDerivative · entry 3 Zuga Matt · CIK 0001790214 · CFO & Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 218,539 F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9500 to $2.0400. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 02:31 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 5,100 | $1.97 | $10,027.62 |
DisclosureSEC source: 0001628280-26-001265 · wk-form4_1767839507.xml · nonDerivative · entry 2 Zuga Matt · CIK 0001790214 · CFO & Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,644 F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9400 to $1.9900. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 05, 2026 Filed Jan 8, 2026 02:31 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 4,000 | $1.96 | $7,842.40 |
DisclosureSEC source: 0001628280-26-001265 · wk-form4_1767839507.xml · nonDerivative · entry 1 Zuga Matt · CIK 0001790214 · CFO & Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 227,744 F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9100 to $1.9750. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 21:00 UTC | ELUTIA INC. ELUT · Entity 7342 | GrantStock Option (Right to Buy) · Derivative | 60,339 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001415889-25-015202 · form4-06022025_050608.xml · derivative · entry 1 Zuga Matt · CIK 0001790214 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,339 Underlying: Class A Common Stock · 60,339 shares Expires 2035-05-29 F1 · derivative.exercise_date: This option was granted automatically under the Issuer's Non-Employee Director Compensation Program and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continuing in service on the Issuer's board of directors through the applicable vesting date. Read SEC document |
| February 03, 2025 Filed Mar 13, 2025 20:28 UTC | ELUTIA INC. ELUT · Entity 7342 | PurchaseClass A Common Stock | 420,000 | $2.50 | $1,050,000.00 |
DisclosureSEC source: 0001104659-25-023484 · tm259106-1_4seq1.xml · nonDerivative · entry 1 HighCape Capital, L.P. · CIK 0001826279 · Director · 10% owner Zuga Matt · CIK 0001790214 · Director · 10% owner RAKIN KEVIN · CIK 0001184421 · Director · 10% owner HighCape Partners GP, LLC · CIK 0001819933 · 10% owner HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner HighCape Capital, LLC · CIK 0001827500 · 10% owner HighCape Partners GP II, L.P. · CIK 0001957359 · 10% owner HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 9,520,232 F1 · ownership.nature: Includes: (i) 53,818 shares of Common Stock held of record by HighCape Partners, L.P.; (ii) 4,001,428 shares of Common Stock held of record by HighCape Partners QP, L.P.; (iii) 499,145 shares of Common Stock held of record by HighCape Co-Investment Vehicle I, LLC; (iv) 259,282 shares of Common Stock held of record by HighCape Co-Investment Vehicle II, LLC; (v) 48,931 shares of Common Stock held of record by HighCape Capital, L.P; (vi) 95,197 shares of Common Stock held of record by HighCape Partners II, L.P.; and (vii) 4,562,431 shares of Common Stock held of record by HighCape Partners QP II, L.P. F2 · ownership.nature: Kevin Rakin and W. Matthew Zuga, members of Issuer's board of directors, are the managing members of HighCape Partners GP, LLC, which is the general partner ("GP") of HighCape Partners GP, L.P., which is the GP of each of HighCape Partners, L.P. and HighCape Partners QP, L.P. Mr. Rakin and Mr. Zuga are the managing members of HighCape Capital, LLC, which is the GP of HighCape Capital, L.P. Mr. Rakin and Mr. Zuga are the managing members of HighCape Partners GP II, LLC, which is the GP of HighCape Partners GP II, L.P., which is the GP of each of HighCape Partners II, L.P. and HighCape Partners QP II, L.P. In addition, HighCape Partners GP, L.P. manages each of HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC. F3 · ownership.nature: Each of Mr. Rakin, Mr. Zuga, HighCape Partners GP, LLC and HighCape Partners GP, L.P. may be deemed to beneficially own the securities held by HighCape Partners, L.P., HighCape Partners QP, L.P., HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC, and each of Mr. Rakin, Mr. Zuga and HighCape Capital, LLC may be deemed to beneficially own the securities held by HighCape Capital, L.P. In addition, each of Mr. Rakin, Mr. Zuga, HighCape Partners GP II, LLC and HighCape Partners GP II, L.P. may be deemed to beneficially own the securities held by HighCape Partners II, L.P. and HighCape Partners QP II, L.P. Each of the reporting persons disclaims beneficial ownership of the securities held by the other reporting persons except to the extent of each reporting person's pecuniary interest therein, if any. Read SEC document |
| January 23, 2025 Filed Jan 24, 2025 02:19 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 28,902 | $1.72 | $49,633.40 |
DisclosureSEC source: 0001576885-25-000037 · wk-form4_1737685161.xml · nonDerivative · entry 2 Zuga Matt · CIK 0001790214 · CFO & Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 231,744 F3 · shares: Represents the number of shares sold by the Reporting Person in connection with the vesting of RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 24, 2024. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.6705 to $1.7699. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 21, 2025 Filed Jan 24, 2025 02:19 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 4,364 | $1.60 | $6,986.33 |
DisclosureSEC source: 0001576885-25-000037 · wk-form4_1737685161.xml · nonDerivative · entry 1 Zuga Matt · CIK 0001790214 · CFO & Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 260,646 F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.5800 to $1.6100. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 00:53 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantEmployee Stock Option (right to buy) · Derivative | 100,300 | $0.00 Strike: $1.85 | $0.00 |
DisclosureSEC source: 0001576885-25-000011 · wk-form4_1736297601.xml · derivative · entry 3 Zuga Matt · CIK 0001790214 · CFO & Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,300 Underlying: Common Stock · 100,300 shares Expires 2035-01-06 F4 · derivative.exercise_date: The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 00:53 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantCommon Stock | 66,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001576885-25-000011 · wk-form4_1736297601.xml · nonDerivative · entry 2 Zuga Matt · CIK 0001790214 · CFO & Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 265,010 F3 · shares: Represents an RSU award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 03, 2025 Filed Jan 8, 2025 00:53 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 13,235 | $1.84 | $24,366.96 |
DisclosureSEC source: 0001576885-25-000011 · wk-form4_1736297601.xml · nonDerivative · entry 1 Zuga Matt · CIK 0001790214 · CFO & Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 198,210 F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7700 to $1.9000. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 30, 2024 Filed Aug 1, 2024 20:54 UTC | ELUTIA INC. ELUT · Entity 7342 | OtherWarrants (right to buy) · Derivative | 2,101,577 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001104659-24-084967 · tm2420609-2_4seq1.xml · derivative · entry 2 HighCape Capital, L.P. · CIK 0001826279 · Director · 10% owner Zuga Matt · CIK 0001790214 · Director · 10% owner RAKIN KEVIN · CIK 0001184421 · Director · 10% owner HighCape Partners GP, LLC · CIK 0001819933 · 10% owner HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner HighCape Partners QP II, L.P. · CIK 0001770972 · 10% owner HighCape Partners GP II, LLC · CIK 0001957360 · 10% owner HighCape Partners GP II, L.P. · CIK 0001957359 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Class A Common Stock · 2,101,577 shares Expires not disclosed F4 · derivative.expiration_date: The warrant has expired. The warrant provided for expiration upon the earlier of (a) 30 trading days after the clearance by the U.S. Food & Drug Administration of the issuer's CanGarooRM antibiotic-eluting biologic envelope (which has elapsed) or (b) September 21, 2028. F2 · ownership.nature: Kevin Rakin and W. Matthew Zuga, members of Issuer's board of directors, are the managing members of HighCape Partners GP, LLC, which is the general partner ("GP") of HighCape Partners GP, L.P., which is the GP of each of HighCape Partners, L.P. and HighCape Partners QP, L.P. Mr. Rakin and Mr. Zuga are the managing members of HighCape Capital, LLC, which is the GP of HighCape Capital, L.P. Mr. Rakin and Mr. Zuga are the managing members of HighCape Partners GP II, LLC, which is the GP of HighCape Partners GP II, L.P., which is the GP of each of HighCape Partners II, L.P. and HighCape Partners QP II, L.P. In addition, HighCape Partners GP, L.P. manages each of HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC. F3 · ownership.nature: Each of Mr. Rakin, Mr. Zuga, HighCape Partners GP, LLC and HighCape Partners GP, L.P. may be deemed to beneficially own the securities held by HighCape Partners, L.P., HighCape Partners QP, L.P., HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC, and each of Mr. Rakin, Mr. Zuga and HighCape Capital, LLC may be deemed to beneficially own the securities held by HighCape Capital, L.P. In addition, each of Mr. Rakin, Mr. Zuga, HighCape Partners GP II, LLC and HighCape Partners GP II, L.P. may be deemed to beneficially own the securities held by HighCape Partners II, L.P. and HighCape Partners QP II, L.P. Each of the reporting persons disclaims beneficial ownership of the securities held by the other reporting persons except to the extent of each reporting person's pecuniary interest therein, if any. F5 · ownership.nature: Warrants for 2,058,623 shares of Common Stock were exercised by HighCape Partners QP II, L.P. and warrants for 42,954 shares of Common Stock were exercised by HighCape Partners II, L.P. Read SEC document |
| July 30, 2024 Filed Aug 1, 2024 20:54 UTC | ELUTIA INC. ELUT · Entity 7342 | OtherClass A Common Stock | 2,101,577 | $1.43 | $3,000,001.17 |
DisclosureSEC source: 0001104659-24-084967 · tm2420609-2_4seq1.xml · nonDerivative · entry 1 HighCape Capital, L.P. · CIK 0001826279 · Director · 10% owner Zuga Matt · CIK 0001790214 · Director · 10% owner RAKIN KEVIN · CIK 0001184421 · Director · 10% owner HighCape Partners GP, LLC · CIK 0001819933 · 10% owner HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner HighCape Partners QP II, L.P. · CIK 0001770972 · 10% owner HighCape Partners GP II, LLC · CIK 0001957360 · 10% owner HighCape Partners GP II, L.P. · CIK 0001957359 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 9,100,232 F1 · ownership.nature: Includes: (i) 53,818 shares of Common Stock held of record by HighCape Partners, L.P.; (ii) 4,001,428 shares of Common Stock held of record by HighCape Partners QP, L.P.; (iii) 499,145 shares of Common Stock held of record by HighCape Co-Investment Vehicle I, LLC; (iv) 259,282 shares of Common Stock held of record by HighCape Co-Investment Vehicle II, LLC; (v) 48,931 shares of Common Stock held of record by HighCape Capital, L.P; (vi) 86,613 shares of Common Stock held of record by HighCape Partners II, L.P.; and (vii) 4,151,015 shares of Common Stock held of record by HighCape Partners QP II, L.P. F2 · ownership.nature: Kevin Rakin and W. Matthew Zuga, members of Issuer's board of directors, are the managing members of HighCape Partners GP, LLC, which is the general partner ("GP") of HighCape Partners GP, L.P., which is the GP of each of HighCape Partners, L.P. and HighCape Partners QP, L.P. Mr. Rakin and Mr. Zuga are the managing members of HighCape Capital, LLC, which is the GP of HighCape Capital, L.P. Mr. Rakin and Mr. Zuga are the managing members of HighCape Partners GP II, LLC, which is the GP of HighCape Partners GP II, L.P., which is the GP of each of HighCape Partners II, L.P. and HighCape Partners QP II, L.P. In addition, HighCape Partners GP, L.P. manages each of HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC. F3 · ownership.nature: Each of Mr. Rakin, Mr. Zuga, HighCape Partners GP, LLC and HighCape Partners GP, L.P. may be deemed to beneficially own the securities held by HighCape Partners, L.P., HighCape Partners QP, L.P., HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC, and each of Mr. Rakin, Mr. Zuga and HighCape Capital, LLC may be deemed to beneficially own the securities held by HighCape Capital, L.P. In addition, each of Mr. Rakin, Mr. Zuga, HighCape Partners GP II, LLC and HighCape Partners GP II, L.P. may be deemed to beneficially own the securities held by HighCape Partners II, L.P. and HighCape Partners QP II, L.P. Each of the reporting persons disclaims beneficial ownership of the securities held by the other reporting persons except to the extent of each reporting person's pecuniary interest therein, if any. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 21:00 UTC | ELUTIA INC. ELUT · Entity 7342 | GrantStock Option (Right to Buy) · Derivative | 31,835 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001415889-24-016249 · form4-06102024_050612.xml · derivative · entry 1 Zuga Matt · CIK 0001790214 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,835 Underlying: Class A Common Stock · 31,835 shares Expires 2034-06-05 F1 · derivative.exercise_date: This option was granted automatically under the Issuer's Non-Employee Director Compensation Program and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continuing in service on the Issuer's board of directors through the applicable vesting date. Read SEC document |
| January 18, 2024 Filed Jan 20, 2024 00:05 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 4,242 | $3.71 | $15,716.61 |
DisclosureSEC source: 0001576885-24-000026 · wk-form4_1705709143.xml · nonDerivative · entry 1 Zuga Matt · CIK 0001790214 · CFO & Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 211,445 F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2023. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:20 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantEmployee Stock Option (right to buy) · Derivative | 159,000 | $0.00 Strike: $4.23 | $0.00 |
DisclosureSEC source: 0001576885-24-000010 · wk-form4_1704403210.xml · derivative · entry 2 Zuga Matt · CIK 0001790214 · CFO & Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 159,000 Underlying: Common Stock · 159,000 shares Expires 2034-01-01 F2 · derivative.exercise_date: The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:20 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantCommon Stock | 106,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001576885-24-000010 · wk-form4_1704403210.xml · nonDerivative · entry 1 Zuga Matt · CIK 0001790214 · CFO & Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,687 F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| December 28, 2023 Filed Jan 8, 2024 21:09 UTC | ELUTIA INC. ELUT · Entity 7342 | OtherWarrants (right to buy) · Derivative | 2,154,116 | Not disclosed Strike: $1.43 | Not disclosed |
DisclosureSEC source: 0001104659-24-002239 · tm242311-2_4seq1.xml · derivative · entry 2 HighCape Capital, L.P. · CIK 0001826279 · Director · 10% owner Zuga Matt · CIK 0001790214 · Director · 10% owner RAKIN KEVIN · CIK 0001184421 · Director · 10% owner HighCape Partners GP, LLC · CIK 0001819933 · 10% owner HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner HighCape Partners QP II, L.P. · CIK 0001770972 · 10% owner HighCape Partners GP II, LLC · CIK 0001957360 · 10% owner HighCape Partners GP II, L.P. · CIK 0001957359 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,101,577 Underlying: Class A Common Stock · 2,154,116 shares Expires not disclosed F7 · kind: This Form 4 relates to the pro rata distribution by Elutia PIPE Investment LP of its shares of Class A Common Stock and Warrants to its partners, without payment of consideration by such partners. F1 · price: The reported securities are included within 1,436,077 Units originally purchased by Elutia PIPE Investment LP for $1.4275 per Unit. Each Unit consists of one share of Class A Common Stock (the "Common Stock") and one warrant to purchase one and one-half shares of Common Stock. The shares of Common Stock and Warrants reported as transferred in this Form 4 are being distributed to Elutia PIPE Investment LP's partners without payment of consideration by them. F5 · derivative.expiration_date: The warrant expires upon the earlier of (a) 30 trading days after the clearance by the U.S. Food & Drug Administration of the issuer's CanGarooRM antibiotic-eluting biologic envelope or (b) September 21, 2028. F6 · ownership.nature: Includes (i) 2,058,623 shares of Common Stock issuable upon exercise of a warrant held by HighCape Partners QP II, L.P.; and (ii) 42,954 shares of Common Stock issuable upon exercise of a warrant held by HighCape Partners II, L.P. Read SEC document |
| December 28, 2023 Filed Jan 8, 2024 21:09 UTC | ELUTIA INC. ELUT · Entity 7342 | OtherClass A Common Stock | 1,436,077 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-002239 · tm242311-2_4seq1.xml · nonDerivative · entry 1 HighCape Capital, L.P. · CIK 0001826279 · Director · 10% owner Zuga Matt · CIK 0001790214 · Director · 10% owner RAKIN KEVIN · CIK 0001184421 · Director · 10% owner HighCape Partners GP, LLC · CIK 0001819933 · 10% owner HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner HighCape Partners QP II, L.P. · CIK 0001770972 · 10% owner HighCape Partners GP II, LLC · CIK 0001957360 · 10% owner HighCape Partners GP II, L.P. · CIK 0001957359 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 6,998,655 F7 · kind: This Form 4 relates to the pro rata distribution by Elutia PIPE Investment LP of its shares of Class A Common Stock and Warrants to its partners, without payment of consideration by such partners. F1 · price: The reported securities are included within 1,436,077 Units originally purchased by Elutia PIPE Investment LP for $1.4275 per Unit. Each Unit consists of one share of Class A Common Stock (the "Common Stock") and one warrant to purchase one and one-half shares of Common Stock. The shares of Common Stock and Warrants reported as transferred in this Form 4 are being distributed to Elutia PIPE Investment LP's partners without payment of consideration by them. F2 · ownership.nature: Includes: (i) 53,818 shares of Common Stock held of record by HighCape Partners, L.P.; (ii) 4,001,428 shares of Common Stock held of record by HighCape Partners QP, L.P.; (iii) 499,145 shares of Common Stock held of record by HighCape Co-Investment Vehicle I, LLC; (iv) 259,282 shares of Common Stock held of record by HighCape Co-Investment Vehicle II, LLC; (v) 48,931 shares of Common Stock held of record by HighCape Capital, L.P; (vi) 43,659 shares of Common Stock held of record by HighCape Partners II, L.P.; and (vii) 2,092,392 shares of Common Stock held of record by HighCape Partners QP II, L.P. F3 · ownership.nature: Kevin Rakin and W. Matthew Zuga, members of Issuer's board of directors, are the managing members of HighCape Partners GP, LLC, which is the general partner ("GP") of HighCape Partners GP, L.P., which is the GP of each of HighCape Partners, L.P. and HighCape Partners QP, L.P. Mr. Rakin and Mr. Zuga are the managing members of HighCape Capital, LLC, which is the GP of HighCape Capital, L.P. Mr. Rakin and Mr. Zuga are the managing members of HighCape Partners GP II, LLC, which is the GP of HighCape Partners GP II, L.P., which is the GP of each of HighCape Partners II, L.P., HighCape Partners QP II, L.P. and Elutia PIPE Investment, LP. In addition, HighCape Partners GP, L.P. manages each of HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC. F4 · ownership.nature: Each of Mr. Rakin, Mr. Zuga, HighCape Partners GP, LLC and HighCape Partners GP, L.P. may be deemed to beneficially own the securities held by HighCape Partners, L.P., HighCape Partners QP, L.P., HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC, and each of Mr. Rakin, Mr. Zuga and HighCape Capital, LLC may be deemed to beneficially own the securities held by HighCape Capital, L.P. In addition, each of Mr. Rakin, Mr. Zuga, HighCape Partners GP II, LLC and HighCape Partners GP II, L.P. may be deemed to beneficially own the securities held by HighCape Partners II, L.P., HighCape Partners QP II, L.P. and Elutia PIPE Investment, LP. Each of the reporting persons disclaims beneficial ownership of the securities held by the other reporting persons except to the extent of each reporting person's pecuniary interest therein, if any. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 19:32 UTC | ELUTIA INC. AZYO · Entity 7342 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.37 | $0.00 |
DisclosureSEC source: 0001104659-23-070300 · tm2318353-1_4seq1.xml · derivative · entry 2 HighCape Capital, L.P. · CIK 0001826279 · Director · 10% owner HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · Director · 10% owner HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · Director · 10% owner HighCape Partners GP, LLC · CIK 0001819933 · Director · 10% owner HighCape Partners GP, L.P. · CIK 0001819932 · Director · 10% owner HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · Director · 10% owner HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · Director · 10% owner HighCape Capital, LLC · CIK 0001827500 · Director · 10% owner Zuga Matt · CIK 0001790214 · Director · 10% owner RAKIN KEVIN · CIK 0001184421 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 25,000 Underlying: Class A Common Stock · 25,000 shares Expires 2033-06-07 F1 · derivative.exercise_date: This option was granted automatically under the Issuer's First Amended and Restated Non-Employee Director Compensation Policy and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to Messrs. Rakin's and Zuga's, as applicable, continuing in service on the Issuer's board of directors through the applicable vesting date. F3 · ownership.nature: Held by W. Matthew Zuga as non-employee member of the Issuer's board of directors. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 19:32 UTC | ELUTIA INC. AZYO · Entity 7342 | GrantStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $2.37 | $0.00 |
DisclosureSEC source: 0001104659-23-070300 · tm2318353-1_4seq1.xml · derivative · entry 1 HighCape Capital, L.P. · CIK 0001826279 · Director · 10% owner HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · Director · 10% owner HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · Director · 10% owner HighCape Partners GP, LLC · CIK 0001819933 · Director · 10% owner HighCape Partners GP, L.P. · CIK 0001819932 · Director · 10% owner HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · Director · 10% owner HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · Director · 10% owner HighCape Capital, LLC · CIK 0001827500 · Director · 10% owner Zuga Matt · CIK 0001790214 · Director · 10% owner RAKIN KEVIN · CIK 0001184421 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 37,500 Underlying: Class A Common Stock · 37,500 shares Expires 2033-06-07 F1 · derivative.exercise_date: This option was granted automatically under the Issuer's First Amended and Restated Non-Employee Director Compensation Policy and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to Messrs. Rakin's and Zuga's, as applicable, continuing in service on the Issuer's board of directors through the applicable vesting date. F2 · ownership.nature: Held by Kevin L. Rakin as non-employee member of the Issuer's board of directors. Read SEC document |
| January 17, 2023 Filed Jan 18, 2023 21:27 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantEmployee Stock Option (right to buy) · Derivative | 150,800 | $0.00 Strike: $6.11 | $0.00 |
DisclosureSEC source: 0001209191-23-003750 · doc4.xml · derivative · entry 2 Zuga Matt · CIK 0001790214 · CFO and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,800 Underlying: Common Stock · 150,800 shares Expires 2033-01-16 F2 · derivative.exercise_date: The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 17, 2023 Filed Jan 18, 2023 21:27 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantCommon Stock | 33,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-003750 · doc4.xml · nonDerivative · entry 1 Zuga Matt · CIK 0001790214 · CFO and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,687 F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| December 29, 2022 Filed Jan 3, 2023 22:23 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | Exercise / conversionStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001209191-23-000327 · doc4.xml · derivative · entry 2 Zuga Matt · CIK 0001790214 · CFO and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 401,369 Underlying: Common Stock · 50,000 shares Expires 2031-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares underlying the option vested and became exercisable on January 1, 2022; the remainder vested or shall vest and become exercisable in 36 equal monthly installments such that the option shall be fully vested on January 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such date. Read SEC document |
| December 29, 2022 Filed Jan 3, 2023 22:23 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | Exercise / conversionCommon Stock | 50,000 | $1.19 | $59,500.00 |
DisclosureSEC source: 0001209191-23-000327 · doc4.xml · nonDerivative · entry 1 Zuga Matt · CIK 0001790214 · CFO and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,187 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 23:09 UTC | ELUTIA INC. AZYO · Entity 7342 | GrantStock Option (Right to Buy) · Derivative | 17,533 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001415889-22-013020 · form4-12272022_111257.xml · derivative · entry 1 HighCape Capital, L.P. · CIK 0001826279 · Director · 10% owner HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner HighCape Partners GP, LLC · CIK 0001819933 · 10% owner HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · Director · 10% owner HighCape Capital, LLC · CIK 0001827500 · 10% owner Zuga Matt · CIK 0001790214 · Director · 10% owner RAKIN KEVIN · CIK 0001184421 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 17,533 Underlying: Class A Common Stock · 17,533 shares Expires 2032-12-21 F1 · derivative.exercise_date: This option vests in full and shall be fully exercisable on June 20, 2023, subject to Mr. Rakin's continuing in service on the Issuer's board of directors through the vesting date. F2 · ownership.nature: Granted to Kevin L. Rakin as non-employee member of the Issuer's board of directors. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 21:31 UTC | ELUTIA INC. AZYO · Entity 7342 | PurchaseClass A Common Stock | 735,000 | $4.75 | $3,491,250.00 |
DisclosureSEC source: 0001104659-22-125197 · tm2232148-1_4seq1.xml · nonDerivative · entry 1 HighCape Capital, L.P. · CIK 0001826279 · Director · 10% owner HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner HighCape Partners GP, LLC · CIK 0001819933 · 10% owner HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · 10% owner HighCape Capital, LLC · CIK 0001827500 · 10% owner Zuga Matt · CIK 0001790214 · Director · 10% owner RAKIN KEVIN · CIK 0001184421 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 5,597,604 F1 · ownership.nature: Includes: (i) 53,818 shares of Class A Common Stock held of record by HighCape Partners, L.P.; (ii) 4,001,428 shares of Class A Common Stock held of record by HighCape Partners QP, L.P.; (iii) 499,145 shares of Class A Common Stock held of record by HighCape Co-Investment Vehicle I, LLC; (iv) 259,282 shares of Class A Common Stock held of record by HighCape Co-Investment Vehicle II, LLC; (v) 48,931 shares of Class A Common Stock held of record by HighCape Capital, L.P.; (vi) 15,023 shares of Class A Common Stock held of record by HighCape Partners II, L.P.; and (vii) 719,977 shares of Class A Common Stock held of record by HighCape Partners QP II, L.P. F2 · ownership.nature: Kevin Rakin and W. Matthew Zuga, members of Issuer's board of directors, are the managing members of HighCape Partners GP, LLC, which is the general partner of HighCape Partners GP, L.P., which is the general partner of each of HighCape Partners, L.P. and HighCape Partners QP, L.P. Messrs. Rakin and Zuga are the managing members of HighCape Capital, LLC, which is the general partner of HighCape Capital, L.P. Messrs. Rakin and Zuga are also the managing members of HighCape Partners GP II, LLC, which is the general partner of HighCape Partners GP II, L.P., which is the general partner of each of HighCape Partners II, L.P. and HighCape Partners QP II, L.P. F3 · ownership.nature: Each of Mr. Rakin, Mr. Zuga, HighCape Partners GP, LLC and HighCape Partners GP, L.P. may be deemed to beneficially own the securities held of record by each of HighCape Partners, L.P. and HighCape Partners QP, L.P. Each of Mr. Rakin, Mr. Zuga and HighCape Capital, LLC may be deemed to beneficially own the securities held of record by HighCape Capital, L.P. Each of Mr. Rakin, Mr. Zuga, HighCape Partners GP II, LLC and HighCape Partners GP II, L.P. may be deemed to beneficially own the securities held of record by each of HighCape Partners II, L.P. and HighCape Partners QP II, L.P. F4 · ownership.nature: In addition, Mr. Zuga is the managing member of each of HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC and may be deemed to beneficially own the securities held of record by each such entity. Mr. Rakin may be deemed to beneficially own the securities held of record by the Kevin L. Rakin Irrevocable Trust. Each of the reporting persons disclaims beneficial ownership of the securities held by the other reporting persons except to the extent of each reporting person's pecuniary interest therein, if any. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 12:28 UTC | ELUTIA INC. AZYO · Entity 7342 | GrantStock Option (Right to Buy) · Derivative | 22,090 | $0.00 Strike: $6.28 | $0.00 |
DisclosureSEC source: 0001415889-22-006330 · form4-06092022_050626.xml · derivative · entry 2 HighCape Capital, L.P. · CIK 0001826279 · Director · 10% owner HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner HighCape Partners GP, LLC · CIK 0001819933 · 10% owner HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · Director · 10% owner HighCape Capital, LLC · CIK 0001827500 · 10% owner Zuga Matt · CIK 0001790214 · Director · 10% owner RAKIN KEVIN · CIK 0001184421 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 22,090 Underlying: Class A Common Stock · 22,090 shares Expires 2032-06-06 F1 · derivative.exercise_date: This option was granted automatically under the Issuer's Non-Employee Director Compensation Program and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to Messrs. Rakin's and Zuga's, as applicable, continuing in service on the Issuer's board of directors through the applicable vesting date. F3 · ownership.nature: Held by W. Matthew Zuga as non-employee member of the Issuer's board of directors. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 12:28 UTC | ELUTIA INC. AZYO · Entity 7342 | GrantStock Option (Right to Buy) · Derivative | 22,090 | $0.00 Strike: $6.28 | $0.00 |
DisclosureSEC source: 0001415889-22-006330 · form4-06092022_050626.xml · derivative · entry 1 HighCape Capital, L.P. · CIK 0001826279 · Director · 10% owner HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner HighCape Partners GP, LLC · CIK 0001819933 · 10% owner HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · Director · 10% owner HighCape Capital, LLC · CIK 0001827500 · 10% owner Zuga Matt · CIK 0001790214 · Director · 10% owner RAKIN KEVIN · CIK 0001184421 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 22,090 Underlying: Class A Common Stock · 22,090 shares Expires 2032-06-06 F1 · derivative.exercise_date: This option was granted automatically under the Issuer's Non-Employee Director Compensation Program and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to Messrs. Rakin's and Zuga's, as applicable, continuing in service on the Issuer's board of directors through the applicable vesting date. F2 · ownership.nature: Held by Kevin L. Rakin as non-employee member of the Issuer's board of directors. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 21:22 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $5.19 | $0.00 |
DisclosureSEC source: 0001209191-22-004427 · doc4.xml · derivative · entry 1 Zuga Matt · CIK 0001790214 · CFO and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2032-01-19 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest and become exercisable on January 19, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest and become exercisable each month thereafter, subject to Reporting Person continuing to provide service through each such date. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 21:22 UTC | ELUTIA INC. AZYO · Entity 7342 | PurchaseClass A Common Stock | 58,962 | $4.24 | $249,998.88 |
DisclosureSEC source: 0001104659-21-148591 · tm2135128-1_4seq1.xml · nonDerivative · entry 2 HighCape Capital, L.P. · CIK 0001826279 · Director · 10% owner HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner HighCape Partners GP, LLC · CIK 0001819933 · 10% owner HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · 10% owner HighCape Capital, LLC · CIK 0001827500 · 10% owner Zuga Matt · CIK 0001790214 · Director · 10% owner RAKIN KEVIN · CIK 0001184421 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Kevin L. Rakin Irrevocable Trust Disclosed balance after: 90,807 Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 21:22 UTC | ELUTIA INC. AZYO · Entity 7342 | PurchaseClass A Common Stock | 353,773 | $4.24 | $1,499,997.52 |
DisclosureSEC source: 0001104659-21-148591 · tm2135128-1_4seq1.xml · nonDerivative · entry 1 HighCape Capital, L.P. · CIK 0001826279 · Director · 10% owner HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner HighCape Partners GP, LLC · CIK 0001819933 · 10% owner HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · 10% owner HighCape Capital, LLC · CIK 0001827500 · 10% owner Zuga Matt · CIK 0001790214 · Director · 10% owner RAKIN KEVIN · CIK 0001184421 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,862,604 F1 · ownership.nature: Includes: (i) 53,818 shares of Common Stock held of record by HighCape Partners, L.P.; (ii) 4,001,428 shares of Common Stock held of record by HighCape Partners QP, L.P.; (iii) 499,145 shares of Common Stock held of record by HighCape Co-Investment Vehicle I, LLC; (iv) 259,282 shares of Common Stock held of record by HighCape Co-Investment Vehicle II, LLC; and (v) 48,931 shares of Common Stock held of record by HighCape Capital, L.P. F2 · ownership.nature: Kevin Rakin and W. Matthew Zuga, members of Issuer's board of directors, are the managing members of HighCape Partners GP, LLC, which is the general partner of HighCape Partners GP, L.P., which is the general partner of each of HighCape Partners, L.P. and HighCape Partners QP, L.P. Mr. Rakin and Mr. Zuga are the managing members of HighCape Capital, LLC, which is the general partner of HighCape Capital, L.P. Each of Mr. Rakin, Mr. Zuga, HighCape Partners GP, LLC and HighCape Partners GP, L.P. may be deemed to beneficially own the securities held by HighCape Partners, L.P. and HighCape Partners QP, L.P., and each of Mr. Rakin, Mr. Zuga and HighCape Capital, LLC may be deemed to beneficially own the securities held by HighCape Capital, L.P. F3 · ownership.nature: In addition, Mr. Zuga is the managing member of each of HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC and may be deemed to beneficially own the securities held by such entities. Each of the reporting persons disclaims beneficial ownership of the securities held by the other reporting persons except to the extent of each reporting person's pecuniary interest therein, if any. Read SEC document |
| September 21, 2021 Filed Oct 5, 2023 20:43 UTC | ELUTIA INC. ELUT · Entity 7342 | PurchaseWarrants (right to buy) · Derivative | 4,255,693 | Not disclosed Strike: $1.43 | Not disclosed |
DisclosureSEC source: 0001826279-23-000002 · primary_doc.xml · derivative · entry 2 HighCape Capital, L.P. · CIK 0001826279 · Director · 10% owner Zuga Matt · CIK 0001790214 · Director · 10% owner RAKIN KEVIN · CIK 0001184421 · Director · 10% owner HighCape Partners GP, LLC · CIK 0001819933 · 10% owner HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner HighCape Partners QP II, L.P. · CIK 0001770972 · 10% owner HighCape Partners GP II, LLC · CIK 0001957360 · 10% owner HighCape Partners GP II, L.P. · CIK 0001957359 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 4,255,693 Underlying: Class A Common Stock · 4,255,693 shares Expires not disclosed F1 · price: The reported securities are included within the 2,837,128 Units purchased by the reporting persons for $1.4275 per Unit. Each Unit consists of one share of Class A Common Stock (the "Common Stock") and one warrant to purchase one and one-half shares of Common Stock. F5 · derivative.expiration_date: The warrant expires upon the earlier of (a) 30 trading days after the clearance by the U.S. Food & Drug Administration of the issuer's CanGarooRM antibiotic-eluting biologic envelope or (b) September 21, 2028. F6 · ownership.nature: Includes (i) 2,058,623 shares of Common Stock issuable upon exercise of a warrant held by HighCape Partners QP II, L.P.; (ii) 42,954 shares of Common Stock issuable upon exercise of a warrant held by HighCape Partners II, L.P; and (iii) 2,154,116 shares of Common Stock issuable upon exercise of a warrant held by Elutia PIPE Investment, LP. Read SEC document |
| September 21, 2021 Filed Oct 5, 2023 20:43 UTC | ELUTIA INC. ELUT · Entity 7342 | PurchaseClass A Common Stock | 2,837,128 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001826279-23-000002 · primary_doc.xml · nonDerivative · entry 1 HighCape Capital, L.P. · CIK 0001826279 · Director · 10% owner Zuga Matt · CIK 0001790214 · Director · 10% owner RAKIN KEVIN · CIK 0001184421 · Director · 10% owner HighCape Partners GP, LLC · CIK 0001819933 · 10% owner HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner HighCape Partners QP II, L.P. · CIK 0001770972 · 10% owner HighCape Partners GP II, LLC · CIK 0001957360 · 10% owner HighCape Partners GP II, L.P. · CIK 0001957359 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 8,434,732 F1 · price: The reported securities are included within the 2,837,128 Units purchased by the reporting persons for $1.4275 per Unit. Each Unit consists of one share of Class A Common Stock (the "Common Stock") and one warrant to purchase one and one-half shares of Common Stock. F2 · ownership.nature: Includes: (i) 53,818 shares of Common Stock held of record by HighCape Partners, L.P.; (ii) 4,001,428 shares of Common Stock held of record by HighCape Partners QP, L.P.; (iii) 499,145 shares of Common Stock held of record by HighCape Co-Investment Vehicle I, LLC; (iv) 259,282 shares of Common Stock held of record by HighCape Co-Investment Vehicle II, LLC; (v) 48,931 shares of Common Stock held of record by HighCape Capital, L.P; (vi) 43,659 shares of Common Stock held of record by HighCape Partners II, L.P.; (vii) 2,092,392 shares of Common Stock held of record by HighCape Partners QP II, L.P.; and (viii) 1,436,077 shares of Common Stock held of record by Elutia PIPE Investment, LP. F3 · ownership.nature: Kevin Rakin and W. Matthew Zuga, members of Issuer's board of directors, are the managing members of HighCape Partners GP, LLC, which is the general partner ("GP") of HighCape Partners GP, L.P., which is the GP of each of HighCape Partners, L.P. and HighCape Partners QP, L.P. Mr. Rakin and Mr. Zuga are the managing members of HighCape Capital, LLC, which is the GP of HighCape Capital, L.P. Mr. Rakin and Mr. Zuga are the managing members of HighCape Partners GP II, LLC, which is the GP of HighCape Partners GP II, L.P., which is the GP of each of HighCape Partners II, L.P., HighCape Partners QP II, L.P. and Elutia PIPE Investment, LP. In addition, HighCape Partners GP, L.P. manages each of HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC. F4 · ownership.nature: Each of Mr. Rakin, Mr. Zuga, HighCape Partners GP, LLC and HighCape Partners GP, L.P. may be deemed to beneficially own the securities held by HighCape Partners, L.P., HighCape Partners QP, L.P., HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC, and each of Mr. Rakin, Mr. Zuga and HighCape Capital, LLC may be deemed to beneficially own the securities held by HighCape Capital, L.P. In addition, each of Mr. Rakin, Mr. Zuga, HighCape Partners GP II, LLC and HighCape Partners GP II, L.P. may be deemed to beneficially own the securities held by HighCape Partners II, L.P., HighCape Partners QP II, L.P. and Elutia PIPE Investment, LP. Each of the reporting persons disclaims beneficial ownership of the securities held by the other reporting persons except to the extent of each reporting person's pecuniary interest therein, if any. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:18 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | ConversionSeries B Preferred Stock · Derivative | 10,528 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-046031 · doc4.xml · derivative · entry 3 Zuga Matt · CIK 0001790214 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,528 Underlying: Common Stock · 10,528 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · price: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:18 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | ConversionSeries A-1 Preferred Stock · Derivative | 15,659 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-046031 · doc4.xml · derivative · entry 2 Zuga Matt · CIK 0001790214 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,659 Underlying: Common Stock · 15,659 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · price: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:18 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | ConversionCommon Stock | 26,187 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-046031 · doc4.xml · nonDerivative · entry 1 Zuga Matt · CIK 0001790214 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,187 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 21:44 UTC | ELUTIA INC. AZYO · Entity 7342 | GrantStock Option (Right to Buy) · Derivative | 14,082 | $0.00 Strike: $10.41 | $0.00 |
DisclosureSEC source: 0001415889-21-002895 · form4-06092021_020617.xml · derivative · entry 2 HighCape Capital, L.P. · CIK 0001826279 · Director · 10% owner HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner HighCape Partners GP, LLC · CIK 0001819933 · 10% owner HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · Director · 10% owner HighCape Capital, LLC · CIK 0001827500 · 10% owner Zuga Matt · CIK 0001790214 · Director · 10% owner RAKIN KEVIN · CIK 0001184421 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 14,082 Underlying: Class A Common Stock · 14,082 shares Expires 2031-06-06 F1 · derivative.exercise_date: This option was granted automatically under the Issuer's Non-Employee Director Compensation Program and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to Messrs. Rakin's and Zuga's, as applicable, continuing in service on the Issuer's board of directors through the applicable vesting date. F3 · ownership.nature: Held by W. Matthew Zuga as non-employee member of the Issuer's board of directors Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 21:44 UTC | ELUTIA INC. AZYO · Entity 7342 | GrantStock Option (Right to Buy) · Derivative | 14,082 | $0.00 Strike: $10.41 | $0.00 |
DisclosureSEC source: 0001415889-21-002895 · form4-06092021_020617.xml · derivative · entry 1 HighCape Capital, L.P. · CIK 0001826279 · Director · 10% owner HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner HighCape Partners GP, LLC · CIK 0001819933 · 10% owner HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · Director · 10% owner HighCape Capital, LLC · CIK 0001827500 · 10% owner Zuga Matt · CIK 0001790214 · Director · 10% owner RAKIN KEVIN · CIK 0001184421 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 14,082 Underlying: Class A Common Stock · 14,082 shares Expires 2031-06-06 F1 · derivative.exercise_date: This option was granted automatically under the Issuer's Non-Employee Director Compensation Program and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to Messrs. Rakin's and Zuga's, as applicable, continuing in service on the Issuer's board of directors through the applicable vesting date. F2 · ownership.nature: Held by Kevin L. Rakin as non-employee member of the Issuer's board of directors Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 01:57 UTC | ELUTIA INC. AZYO · Entity 7342 | OtherWarrant · Derivative | 7,655 | $0.00 Strike: $5.44 | $0.00 |
DisclosureSEC source: 0001104659-20-114637 · a4.xml · derivative · entry 7 HighCape Capital, L.P. · CIK 0001826279 · 10% owner HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner HighCape Partners GP, LLC · CIK 0001819933 · 10% owner HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · 10% owner HighCape Capital, LLC · CIK 0001827500 · 10% owner Zuga Matt · CIK 0001790214 · Director · 10% owner RAKIN KEVIN · CIK 0001184421 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 0 Underlying: Class A Common Stock · 7,655 shares Expires 2027-03-01 F2 · ownership.nature: Kevin Rakin and W. Matthew Zuga, members of Issuer's board of directors, are the managing members of HighCape Partners GP, LLC, which in turn is the general partner of HighCape Partners GP, L.P., which in turn is the general partner of each of HighCape Partners, L.P. and HighCape Partners QP, L.P. Mr. Rakin and Mr. Zuga are the managing members of HighCape Capital, LLC, which in turn is the general partner of HighCape Capital, L.P. Each of Mr. Rakin, Mr. Zuga, HighCape Partners GP, LLC and HighCape Partners GP, L.P. may be deemed to beneficially own the securities held by HighCape Partners, L.P. and HighCape Partners QP, L.P., and each of Mr. Rakin, Mr. Zuga and HighCape Capital, LLC may be deemed to beneficially own the securities held by HighCape Capital, L.P. F4 · ownership.nature: HighCape Partners QP, L.P. is the record holder of these securities. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 01:57 UTC | ELUTIA INC. AZYO · Entity 7342 | ConversionSeries A Convertible Preferred Stock · Derivative | 31,133,977 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-114637 · a4.xml · derivative · entry 6 HighCape Capital, L.P. · CIK 0001826279 · 10% owner HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner HighCape Partners GP, LLC · CIK 0001819933 · 10% owner HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · 10% owner HighCape Capital, LLC · CIK 0001827500 · 10% owner Zuga Matt · CIK 0001790214 · Director · 10% owner RAKIN KEVIN · CIK 0001184421 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 0 Underlying: Class A Common Stock · 4,062,451 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each share of Series A preferred stock was automatically converted into 0.071659417 shares of Class A common stock upon the closing of the Issuer's initial public offering. In addition, immediately prior to the consummation of the Issuer's underwritten initial public offering of its Class A common stock, each holder of Series A preferred stockholders received, for each share of Series A preferred stock then held, 0.820876470 shares of Class A common stock (the quotient of $13.9549 divided by $17.00, the price per share of Class A common stock in such offering). F6 · derivative.exercise_date: Each share of Series A preferred stock was automatically converted into 0.071659417 shares of Class A common stock upon the closing of the Issuer's initial public offering. In addition, immediately prior to the consummation of the Issuer's underwritten initial public offering of its Class A common stock, each holder of Series A preferred stockholders received, for each share of Series A preferred stock then held, 0.820876470 shares of Class A common stock (the quotient of $13.9549 divided by $17.00, the price per share of Class A common stock in such offering). F6 · derivative.expiration_date: Each share of Series A preferred stock was automatically converted into 0.071659417 shares of Class A common stock upon the closing of the Issuer's initial public offering. In addition, immediately prior to the consummation of the Issuer's underwritten initial public offering of its Class A common stock, each holder of Series A preferred stockholders received, for each share of Series A preferred stock then held, 0.820876470 shares of Class A common stock (the quotient of $13.9549 divided by $17.00, the price per share of Class A common stock in such offering). F1 · ownership.nature: Consists of (i) 43,255 shares of Class A common stock held by HighCape Partners, L.P.; (ii) 3,211,838 shares of Class A common stock held by HighCape Partners QP, L.P.; (iii) 499,145 shares of Class A common stock held by HighCape Co-Investment Vehicle I, LLC; (iv) 259,282 shares of Class A common stock held by HighCape Co-Investment Vehicle II, LLC and (v) 48,931 shares of Class A common stock held by HighCape Capital, L.P. F2 · ownership.nature: Kevin Rakin and W. Matthew Zuga, members of Issuer's board of directors, are the managing members of HighCape Partners GP, LLC, which in turn is the general partner of HighCape Partners GP, L.P., which in turn is the general partner of each of HighCape Partners, L.P. and HighCape Partners QP, L.P. Mr. Rakin and Mr. Zuga are the managing members of HighCape Capital, LLC, which in turn is the general partner of HighCape Capital, L.P. Each of Mr. Rakin, Mr. Zuga, HighCape Partners GP, LLC and HighCape Partners GP, L.P. may be deemed to beneficially own the securities held by HighCape Partners, L.P. and HighCape Partners QP, L.P., and each of Mr. Rakin, Mr. Zuga and HighCape Capital, LLC may be deemed to beneficially own the securities held by HighCape Capital, L.P. F3 · ownership.nature: In addition, Mr. Zuga is the managing member of each of HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC and may be deemed to beneficially own the securities held by such entities. Each of the reporting persons disclaims beneficial ownership of the securities held by the other reporting persons except to the extent of each reporting person's pecuniary interest therein, if any. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 01:57 UTC | ELUTIA INC. AZYO · Entity 7342 | PurchaseClass A Common Stock | 441,176 | $17.00 | $7,499,992.00 |
DisclosureSEC source: 0001104659-20-114637 · a4.xml · nonDerivative · entry 4 HighCape Capital, L.P. · CIK 0001826279 · 10% owner HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner HighCape Partners GP, LLC · CIK 0001819933 · 10% owner HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · 10% owner HighCape Capital, LLC · CIK 0001827500 · 10% owner Zuga Matt · CIK 0001790214 · Director · 10% owner RAKIN KEVIN · CIK 0001184421 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 4,508,831 F2 · ownership.nature: Kevin Rakin and W. Matthew Zuga, members of Issuer's board of directors, are the managing members of HighCape Partners GP, LLC, which in turn is the general partner of HighCape Partners GP, L.P., which in turn is the general partner of each of HighCape Partners, L.P. and HighCape Partners QP, L.P. Mr. Rakin and Mr. Zuga are the managing members of HighCape Capital, LLC, which in turn is the general partner of HighCape Capital, L.P. Each of Mr. Rakin, Mr. Zuga, HighCape Partners GP, LLC and HighCape Partners GP, L.P. may be deemed to beneficially own the securities held by HighCape Partners, L.P. and HighCape Partners QP, L.P., and each of Mr. Rakin, Mr. Zuga and HighCape Capital, LLC may be deemed to beneficially own the securities held by HighCape Capital, L.P. F3 · ownership.nature: In addition, Mr. Zuga is the managing member of each of HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC and may be deemed to beneficially own the securities held by such entities. Each of the reporting persons disclaims beneficial ownership of the securities held by the other reporting persons except to the extent of each reporting person's pecuniary interest therein, if any. F5 · ownership.nature: Consists of (i) 49,118 shares of Class A common stock held by HighCape Partners, L.P.; (ii) 3,652,355 shares of Class A common stock held by HighCape Partners QP, L.P.; (iii) 499,145 shares of Class A common stock held by HighCape Co-Investment Vehicle I, LLC; (iv) 259,282 shares of Class A common stock held by HighCape Co-Investment Vehicle II, LLC and (v) 48,931 shares of Class A common stock held by HighCape Capital, L.P. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 01:57 UTC | ELUTIA INC. AZYO · Entity 7342 | Tax withholdingClass A Common Stock | 2,451 | $5.44 | $13,339.32 |
DisclosureSEC source: 0001104659-20-114637 · a4.xml · nonDerivative · entry 3 HighCape Capital, L.P. · CIK 0001826279 · 10% owner HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner HighCape Partners GP, LLC · CIK 0001819933 · 10% owner HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · 10% owner HighCape Capital, LLC · CIK 0001827500 · 10% owner Zuga Matt · CIK 0001790214 · Director · 10% owner RAKIN KEVIN · CIK 0001184421 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 4,067,655 F2 · ownership.nature: Kevin Rakin and W. Matthew Zuga, members of Issuer's board of directors, are the managing members of HighCape Partners GP, LLC, which in turn is the general partner of HighCape Partners GP, L.P., which in turn is the general partner of each of HighCape Partners, L.P. and HighCape Partners QP, L.P. Mr. Rakin and Mr. Zuga are the managing members of HighCape Capital, LLC, which in turn is the general partner of HighCape Capital, L.P. Each of Mr. Rakin, Mr. Zuga, HighCape Partners GP, LLC and HighCape Partners GP, L.P. may be deemed to beneficially own the securities held by HighCape Partners, L.P. and HighCape Partners QP, L.P., and each of Mr. Rakin, Mr. Zuga and HighCape Capital, LLC may be deemed to beneficially own the securities held by HighCape Capital, L.P. F3 · ownership.nature: In addition, Mr. Zuga is the managing member of each of HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC and may be deemed to beneficially own the securities held by such entities. Each of the reporting persons disclaims beneficial ownership of the securities held by the other reporting persons except to the extent of each reporting person's pecuniary interest therein, if any. F4 · ownership.nature: HighCape Partners QP, L.P. is the record holder of these securities. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 01:57 UTC | ELUTIA INC. AZYO · Entity 7342 | OtherClass A Common Stock | 7,655 | $5.44 | $41,661.57 |
DisclosureSEC source: 0001104659-20-114637 · a4.xml · nonDerivative · entry 2 HighCape Capital, L.P. · CIK 0001826279 · 10% owner HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner HighCape Partners GP, LLC · CIK 0001819933 · 10% owner HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · 10% owner HighCape Capital, LLC · CIK 0001827500 · 10% owner Zuga Matt · CIK 0001790214 · Director · 10% owner RAKIN KEVIN · CIK 0001184421 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 4,070,106 F2 · ownership.nature: Kevin Rakin and W. Matthew Zuga, members of Issuer's board of directors, are the managing members of HighCape Partners GP, LLC, which in turn is the general partner of HighCape Partners GP, L.P., which in turn is the general partner of each of HighCape Partners, L.P. and HighCape Partners QP, L.P. Mr. Rakin and Mr. Zuga are the managing members of HighCape Capital, LLC, which in turn is the general partner of HighCape Capital, L.P. Each of Mr. Rakin, Mr. Zuga, HighCape Partners GP, LLC and HighCape Partners GP, L.P. may be deemed to beneficially own the securities held by HighCape Partners, L.P. and HighCape Partners QP, L.P., and each of Mr. Rakin, Mr. Zuga and HighCape Capital, LLC may be deemed to beneficially own the securities held by HighCape Capital, L.P. F3 · ownership.nature: In addition, Mr. Zuga is the managing member of each of HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC and may be deemed to beneficially own the securities held by such entities. Each of the reporting persons disclaims beneficial ownership of the securities held by the other reporting persons except to the extent of each reporting person's pecuniary interest therein, if any. F4 · ownership.nature: HighCape Partners QP, L.P. is the record holder of these securities. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 01:57 UTC | ELUTIA INC. AZYO · Entity 7342 | ConversionClass A Common Stock | 4,062,451 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-114637 · a4.xml · nonDerivative · entry 1 HighCape Capital, L.P. · CIK 0001826279 · 10% owner HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner HighCape Partners GP, LLC · CIK 0001819933 · 10% owner HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · 10% owner HighCape Capital, LLC · CIK 0001827500 · 10% owner Zuga Matt · CIK 0001790214 · Director · 10% owner RAKIN KEVIN · CIK 0001184421 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 4,062,451 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: Consists of (i) 43,255 shares of Class A common stock held by HighCape Partners, L.P.; (ii) 3,211,838 shares of Class A common stock held by HighCape Partners QP, L.P.; (iii) 499,145 shares of Class A common stock held by HighCape Co-Investment Vehicle I, LLC; (iv) 259,282 shares of Class A common stock held by HighCape Co-Investment Vehicle II, LLC and (v) 48,931 shares of Class A common stock held by HighCape Capital, L.P. F2 · ownership.nature: Kevin Rakin and W. Matthew Zuga, members of Issuer's board of directors, are the managing members of HighCape Partners GP, LLC, which in turn is the general partner of HighCape Partners GP, L.P., which in turn is the general partner of each of HighCape Partners, L.P. and HighCape Partners QP, L.P. Mr. Rakin and Mr. Zuga are the managing members of HighCape Capital, LLC, which in turn is the general partner of HighCape Capital, L.P. Each of Mr. Rakin, Mr. Zuga, HighCape Partners GP, LLC and HighCape Partners GP, L.P. may be deemed to beneficially own the securities held by HighCape Partners, L.P. and HighCape Partners QP, L.P., and each of Mr. Rakin, Mr. Zuga and HighCape Capital, LLC may be deemed to beneficially own the securities held by HighCape Capital, L.P. F3 · ownership.nature: In addition, Mr. Zuga is the managing member of each of HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC and may be deemed to beneficially own the securities held by such entities. Each of the reporting persons disclaims beneficial ownership of the securities held by the other reporting persons except to the extent of each reporting person's pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.